245 related articles for article (PubMed ID: 15899725)
41. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
42. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
43. Sirolimus use in de "novo renal" transplantation.
Grinyo JM; Alonso A; Arias M; Campistol JM; González Molina M; González Posada JM; Morales JM; Oppenheimer F; Sánchez Fructuoso A; Sánchez-Plumed J; Ruiz JC
Nefrologia; 2006; 26 Suppl 2():33-51. PubMed ID: 17937633
[No Abstract] [Full Text] [Related]
44. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation.
Formica RN; Lorber KM; Friedman AL; Bia MJ; Lakkis F; Smith JD; Lorber MI
Transplant Proc; 2003 May; 35(3 Suppl):95S-98S. PubMed ID: 12742475
[TBL] [Abstract][Full Text] [Related]
45. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
46. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
47. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
48. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
Ekberg H; Bernasconi C; Nöldeke J; Yussim A; Mjörnstedt L; Erken U; Ketteler M; Navrátil P
Nephrol Dial Transplant; 2010 Jun; 25(6):2004-10. PubMed ID: 20106825
[TBL] [Abstract][Full Text] [Related]
49. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
[TBL] [Abstract][Full Text] [Related]
50. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
Tsai MK; Chueh SC; Hu RH; Lee PH
J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
[TBL] [Abstract][Full Text] [Related]
51. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
[TBL] [Abstract][Full Text] [Related]
52. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.
Sansone-Parsons A; Krishna G; Martinho M; Kantesaria B; Gelone S; Mant TG
Pharmacotherapy; 2007 Jun; 27(6):825-34. PubMed ID: 17542765
[TBL] [Abstract][Full Text] [Related]
53. Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K
Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
[TBL] [Abstract][Full Text] [Related]
54. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
[TBL] [Abstract][Full Text] [Related]
56. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
57. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
58. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
59. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
[TBL] [Abstract][Full Text] [Related]
60. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
